

**ORIC Pharmaceuticals, Inc.**  
**240 E. Grand Ave, 2nd Floor**  
**South San Francisco, California 94080**

January 31, 2024

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Tim Buchmiller, Staff Attorney

**Re: ORIC Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-276719**

**Acceleration Request**

**Requested Date: February 2, 2024**  
**Requested Time: 4:00 p.m. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, ORIC Pharmaceuticals, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-276719) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Amanda Urquiza at (650) 849-3032.

*[Signature page follows]*

---

Sincerely,

**ORIC Pharmaceuticals, Inc.**

/s/ Jacob M. Chacko, M.D.

Jacob M. Chacko, M.D.

President and Chief Executive Officer

cc: Christian Kuhlen, ORIC Pharmaceuticals, Inc.  
Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C.  
Amanda N. Urquiza, Wilson Sonsini Goodrich & Rosati, P.C.